• Explore /
  • Poster
  • / Infigratinib and treatment response in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings.

Infigratinib and treatment response in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings.

Abstract Video & Slides Poster

Authors

Yung Lyou

Yung Lyou

City of Hope Comprehensive Cancer Center, Duarte, CA

Yung Lyou , Petros Grivas , Jonathan E. Rosenberg , Jean H. Hoffman-Censits , David I. Quinn , Daniel Peter Petrylak , Matt D. Galsky , Ulka N. Vaishampayan , Ugo De Giorgi , Sumati Gupta , Howard A. Burris III , Jessica Rearden , Corina Andresen , Hao Wang , Siamak Daneshmand , Dean F. Bajorin , Sumanta K. Pal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT01004224

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5038)

DOI

10.1200/JCO.2020.38.15_suppl.5038

Abstract #

5038

Poster Bd #

107

Abstract Disclosures

Similar Posters

First Author: Nazli Dizman

First Author: Yung Lyou

First Author: Petros Grivas

First Author: Suzanne Cole